Almusalami Eman M, Lockett Anthony, Ferro Albert, Posner John
Centre for Pharmaceutical Medicine Research, King's College London, London, United Kingdom.
School of Cardiovascular and Metabolic Medicine and Sciences, British Heart Foundation Centre for Research Excellence, King's College London, London, United Kingdom.
Front Med (Lausanne). 2023 Mar 16;10:1135695. doi: 10.3389/fmed.2023.1135695. eCollection 2023.
Serum amyloid-A (SAA) is associated with inflammatory disorders such as rheumatoid arthritis, Familial Mediterranean Fever, sarcoidosis, and vasculitis. There is accumulating evidence that SAA is a reliable biomarker for these autoinflammatory and rheumatic diseases and may contribute to their pathophysiology. Hyperinflammatory syndrome associated with COVID-19 is a complex interaction between infection and autoimmunity and elevation of SAA is strongly correlated with severity of the inflammation. In this review we highlight the involvement of SAA in these different inflammatory conditions, consider its potential role and discuss whether it could be a potential target for treatment of the hyperinflammatory state of COVID-19 with many potential advantages and fewer adverse effects. Additional studies linking SAA to the pathophysiology of COVID-19 hyper-inflammation and autoimmunity are needed to establish the causal relationship and the therapeutic potential of inhibitors of SAA activity.
血清淀粉样蛋白A（SAA）与类风湿性关节炎、家族性地中海热、结节病和血管炎等炎症性疾病有关。越来越多的证据表明，SAA是这些自身炎症性和风湿性疾病的可靠生物标志物，可能在其病理生理学中发挥作用。与COVID-19相关的高炎症综合征是感染与自身免疫之间的复杂相互作用，SAA升高与炎症严重程度密切相关。在这篇综述中，我们强调了SAA在这些不同炎症状态中的作用，探讨了其潜在作用，并讨论了它是否可能成为治疗COVID-19高炎症状态的潜在靶点，该靶点具有许多潜在优势且副作用较少。需要更多将SAA与COVID-19高炎症和自身免疫病理生理学联系起来的研究，以确定SAA活性抑制剂的因果关系和治疗潜力。
